Moderna Stock Slashes Hefty Premarket Gain With A Beat That's …

Nov 7, 2024 · Moderna stock closed down 2.9% at 50.29. That pulled back from a bigger 9.4% gain in earlier action. Moderna stock has a poor IBD Digital Relative Strength Rating of 5. This …

CouponFollow Extension

9%
OFF

Moderna Stock Slashes Hefty Premarket Gain With A Beat That's …

2 weeks from now

Nov 7, 2024 · Moderna stock closed down 2.9% at 50.29. That pulled back from a bigger 9.4% gain in earlier action. Moderna stock has a poor IBD Digital Relative Strength Rating of 5. This …

investors.com

$6
OFF

Moderna Shares Slip Premarket As Analysts Cut Ratings Amid …

2 weeks from now

Sep 13, 2024 · On Thursday, Moderna's stock price plunged close to a four-year low after the company said it now expects to have $6 billion in operating cash to break even by 2028, two …

yahoo.com

$1
OFF

Moderna Slashes Hefty Premarket Gain With A Beat That's 'Not A …

2 weeks from now

Covid Sales Drive Beat. Together, the RSV vaccine and Moderna's Covid shot generated $1.9 billion in sales. That handily beat expectations for $1.25 billion.

msn.com

20%
OFF

Moderna Stock Takes A 20% Hit: Here’s Why - MSN

2 weeks from now

Moderna Inc (NASDAQ: MRNA) tanked as much as 20% in premarket on Monday after lowering its full-year sales guidance by about $1.0 billion. The biotech giant cited headwinds as it …

msn.com

96%
OFF

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

2 weeks from now

Oct 14, 2024 · The most recent trading session ended with Moderna (MRNA) standing at $57.73, reflecting a -0.96% shift from the previouse trading day's closing. This change lagged the S&P …

nasdaq.com

17%
OFF

Moderna Stock Plummets 17% On 2025 Sales Guidance Slash

2 weeks from now

Jan 14, 2025 · Moderna reduced its previously announced sales guidance for 2025 by $1 billion. It now forecasts total revenues in the range of $1.5 to $2.5 billion, mainly from product sales of …

yahoo.com

79%
OFF

Down 79%, Is Moderna Stock A Bad-News Buy On The Dip?

2 weeks from now

Jan 16, 2025 · The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are …

yahoo.com

5%
OFF

Moderna’s Stock Jumps 5% Premarket After Narrower-than

2 weeks from now

Aug 3, 2023 · Moderna Inc.’s stock MRNA rallied 5.5% in premarket trade Thursday, after the COVID vaccine market posted a narrower-than-expected second-quarter loss and revenue …

marketwatch.com

$13
OFF

Moderna's Stock Pops After Biotech Ekes Out A Surprise Profit, And ...

2 weeks from now

Nov 7, 2024 · Cambridge, Mass.-based Moderna (MRNA) had a net profit of $13 million, or 3 cents a share, for the quarter, after a loss of $3.6 billion, or $9.53 a share, in the year-earlier …

morningstar.com

11%
OFF

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion

2 weeks from now

Moderna Slashes Hefty Premarket Gain With A Beat That's 'Not A Beat' IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks. Want More IBD Insights? Subscribe To …

msn.com

$9.96
OFF

Moderna Stock Pops On Unexpectedly Strong Covid Vaccine Sales ...

2 weeks from now

Feb 24, 2022 · Revenue and earnings easily beat Moderna stock analysts' projection for earnings of $9.96 per share on $6.8 billion in sales, according to FactSet. ... Moderna Slashes Hefty …

investors.com

28%
OFF

Option Trade On Volatile Moderna Stock Could Return 28% By …

2 weeks from now

May 30, 2024 · Moderna stock option trade works if the stock price stays between 118.90 and 181.10. The idea is to profit from time decay. ... Moderna Slashes Hefty Premarket Gain With …

investors.com

3%
OFF

Vaccine Stocks Moderna, Novavax Pop; Moderna Leads Omicron …

2 weeks from now

Dec 20, 2021 · Moderna stock reversed its fortunes from earlier in the day and dropped 6.3% to close at 276.38. Shares were up considerably earlier in the session. ... Moderna Slashes Hefty …

investors.com

FAQs about Moderna Stock Slashes Hefty Premarket Gain With A Beat That's … Coupon?

Why did Moderna stock take a 20% hit?

The post Moderna stock takes a 20% hit: here's why appeared first on Invezz Moderna Inc (NASDAQ: MRNA) tanked as much as 20% in premarket on Monday after lowering its full-year sales guidance by about $1.0 billion. The biotech giant cited headwinds as it revised its outlook to $1.5 billion to $2.5 billion in sales for 2025. ...

Why did Moderna beat its earnings forecast?

He noted Moderna's beat stemmed from sales of Covid vaccine, Spikevax, which occurred in the third quarter as opposed to the fourth. This is evidenced by the fact Moderna retained its full-year outlook for $3 billion to $3.5 billion in sales. Further, sales of the respiratory syncytial virus vaccine, mResvia, came in well below expectations. ...

Why did Moderna (mRNA) stock jump Thursday?

Moderna ( MRNA) stock jumped Thursday on an unexpected first-quarter gain even as sales plummeted amid waning demand for Covid vaccines. During the first quarter, Moderna earned 19 cents per share. Earnings crashed 98% year over year. But Moderna shocked Wall Street when it turned a profit. Analysts had projected a per-share loss of $1.75. ...

Why did Moderna stock fall 17% on Monday?

Shares of Moderna were down nearly 17% on Monday, likely due to the guidance cut. This revised guidance fell significantly below Wall Street expectations. The Zacks Consensus Estimate for 2025 revenues is $2.94 billion. In the past year, the stock has plunged nearly 67% compared with the industry’s 16.3% fall. ...

Is Moderna a good stock to buy?

Moderna stock has a poor IBD DigitalRelative Strength Rating of 5. This puts the stock's 12-month performance in the bottom 5% of all stocks. Shares also have a low Composite Rating of 6 out of a best-possible 99, a reflection of weak fundamental and technical metrics. ...

Why did Moderna (mRNA) stock rally 5% in premarket trade?

Moderna Inc.’s stock MRNA, +0.42% rallied 5.5% in premarket trade Thursday, after the COVID vaccine market posted a narrower-than-expected second-quarter loss and revenue that was far below last year’s but still topped consensus estimates. ...